A drug for Alzheimer's, donanemab, is considered effective by FDA advisors for early-stage patients, although it doesn't reverse symptoms, leading to questions on its sustained impact.
Donanemab, an amyloid-targeting antibody by Eli Lilly, shows to slow cognitive decline compared to a placebo, similar to a rival drug lecanemab, but not reversing Alzheimer's progression.
[
add
]
[
|
|
...
]